Angiotech to participate in Jefferies Healthcare Conference

    VANCOUVER, June 27 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, is
scheduled to participate in the Jefferies Healthcare Conference, which is
being held June 26 - June 28, 2007 in New York.
    On Thursday, June 28 at 3:10pm ET, Mr. Thomas Bailey, Chief Financial
Officer of Angiotech, will present a 15-minute overview of the Company,
followed by a ten-minute Question and Answer session.
    A link to the audio webcast of Mr. Bailey's remarks will be available to
all interested parties on Angiotech's website at in
the Investors section for 90 days following the event.

    Note on Forward Looking Statements:

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements in this release include but are not limited to
statements regarding; financial benefits to Angiotech that could potentially
be realized from Angiotech's wound closure business, the ability of Angiotech
to commercialize the Quill(R) SRS product and to develop and commercialize any
successive product lines, that a substantial market exists for the product,
that the product will perform as expected, that the product represents an
improvement over current wound closure methods and that these improvements
could be beneficial to physicians and to patients. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following; general
economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or the failure
to comply with, governmental regulations; decisions, and the timing of
decisions, made by health regulatory agencies regarding approval of our
technology and products; the requirement for substantial funding to conduct
research and development and to expand commercialization activities; and any
other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this report to differ
materially from our actual results. These operating risks include; poor
performance of the product in the clinical setting; adverse events related to
the use of the product; improper estimation of the size of the wound closure
market; adverse results or unexpected delays in clinical development
processes; our ability to attract and retain qualified personnel; our ability
to successfully complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection resulting from
third party challenges to our patents; commercialization limitations imposed
by patents owned or controlled by third parties; our ability to obtain rights
to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; our ability to continue to integrate into
our business the operations of American Medical Instruments Holdings, Inc. and
our ability to achieve the operational and other synergies and the other
commercial or financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and other filings
with the applicable Canadian securities regulatory authorities or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

For further information:

For further information: Deirdre Neary, Manager, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890